Hints and tips:
Related Special Reports
...And they certainly go into a level of detail that the agency [FTC] didn’t go into, let’s say, even in a transaction like the [2009, $68bn] Pfizer-Wyeth combination — a mega-deal like that.”...
...He initially showed little interest in megamergers of the kind Pfizer carried out in the prior decade with Wyeth and Warner-Lambert....
...They set up their own research laboratories, helping to bring scientific credibility to a fledgling industry hitherto notorious for quackery....
...That was what happened in the last big round of consolidation, around the turn of the millennium, through Glaxo Wellcome’s merger with SmithKline Beecham and Pfizer’s with Warner-Lambert and Wyeth....
...Yet no amount of marketing could make up for the dearth of new medicines coming out of Pfizer’s laboratories....
...At the heart of debate over the future of AstraZeneca is a simple question: In whose hands would the pharmaceutical company’s laboratories produce the most valuable drugs?...
...In the five years since Pfizer bought Wyeth, it has cut about half the total research and development spending made by the two companies the year before the deal....
...For Pfizer, a deal would add to its history of megamergers, including its $69bn takeover of Wyeth in 2009 and its $111.8bn deal with Warner-Lambert in 2000....
...The Beijing Times reported that Abbott Laboratories, Danone and Mead Johnson Nutrition were also involved in the probe, along with Wyeth Nutrition, now owned by Nestlé....
...Large pharmaceutical companies expanded on the back of “blockbuster” drugs that allowed them to invest in expensive new laboratories and offices....
...But much recent activity has instead focused on divestments, including spinoffs by Pfizer in the wake of its Wyeth purchase and by GlaxoSmithKline of some consumer products....
...Isomeride, a related compound, was withdrawn in the US in 1997, triggering litigation for Wyeth, Servier’s partner, and a fresh examination of benfluorex....
...The unit sells formulation and drug-optimisation technologies to third-party customers such as Merck, Wyeth and Abbott....
...For example, one rationale behind Pfizer’s takeover of Wyeth last year was to defer the pain of patent expiries....
...Pfizer last year paid $68bn to acquire its smaller US rival Wyeth, while Abbott Laboratories of the US bought Solvay of Belgium’s pharmaceuticals business for $6.5bn....
...Forest Laboratories’ UK division bought the Bisodol brand of indigestion products from Wyeth in 2004 and acquired the 70-year old nappy-rash treatment Sudocrem when it bought the Irish company Tosara in...
...Abbott Laboratories on Monday announced the €4.5bn ($6.6bn) acquisition of Solvay’s pharmaceutical company, bringing a five-month takeover battle to an end and highlighting continued consolidation in the...
...“It’s unusual to find a group of people who can combine expertise in such a range of technologies with the ability to link this to the market place,” says Jeff Paslay, a scientist at Wyeth, a US pharmaceutical...
...Although prescriptions are rising, their value is falling as the new generation of antidepressants introduced during the 1980s and 1990s, such as Eli Lilly’s Prozac and Wyeth’s Effexor, lose their patent...
...Monday’s deals follow Pfizer’s agreement earlier this year to acquire Wyeth, what the Journal terms one of the relatively few big pharma companies known for its vaccine expertise....
...Abbott Laboratories of the US has edged ahead of UCB of Belgium and Nycomed of Switzerland in the contest, according to people close to the situation....
...Solvay has whittled down the list of bidders for its pharmaceuticals business to Nycomed, the privately held Swiss company, and Abbott Laboratories of the US....
...Cost cutting in the wake of recent deals, such as Pfizer’s $68bn purchase of Wyeth and Merck’s $41bn takeover of Schering-Plough, will help offset the fall in revenues as drug patents expire....
...Last year brought an extraordinary range of mega-mergers, with Pfizer paying $68bn (£45bn, €50bn) for Wyeth, Merck $41bn for Schering-Plough, and Roche spending $47bn to buy out the minority shareholders...
...GlaxoSmithKline, the pharmaceutical group, has agreed to pay up to $3.6bn (£2.5bn) for Stiefel Laboratories of the US, significantly boosting its presence in dermatology as part of a growing portfolio of...
International Edition